Prostate cancer | Flatiron Health

Plasma circulating tumor DNA (ctDNA) fraction and real-world overall survival (rwOS) in metastatic castration resistant prostate cancer (mCRPC) →

Graf, RP, Li, G, Madison, RW, Schrock, AB, Huang, RSP, Oxnard, G, Venstrom, JM, Castellanos, EH, Snow, T, Swaminathan, A

June 2021

Abstract

ASCO Annual Meeting

Flatiron-authored

Molecular, immunologic, and clinicodemographic landscape of MYC-amplified (MYCamp) advanced prostate cancer (PCa) →

Mahal, BA, Zhang, L, Alshalalfa, M, Graf, RP, Tukachinsky, H, Huang, RSP, McGregor, K, Schrock, AB, Venstrom, JM

June 2021

Abstract

ASCO Annual Meeting

Real-world overall survival and time to therapy discontinuation of patients with mCRPC treated with second-generation novel hormonal therapies associated with tissue-based comprehensive genomic profiling →

Graf, RP, Madison, RW, Gjoerup, O, Zhong, L, Morley, S, Chopra, S, Comment, L, Fisher, V, Li, G, MGregor, K, Schrock, AB, Tukachinsky, H, Snow, T, Cho-Phan, C, Swaminathan, A, Ross, JS, McCusker, M, Zurita, AJ, Venstrom, JM

February 2021

Abstract

ASCO GU Symposium

Flatiron-authored

Real-world clinical outcomes study of sequential novel antihormonal therapy or radium-223 treatment of metastatic castration-resistant prostate cancer that progressed after first-line NAH →

Sartor, AO, George, DJ, Tombal, B, Higano, CS, Sternberg, CN, Miller, K, Jiao, X, Guo, H, Sandstrom, P, Verholen, F, Saad, F, Shore, ND

February 2021

Abstract

ASCO GU Symposium

Overall survival of patients with metastatic castrate-resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss of function →

Gupta, S, Abbass, IM, Craggs, C, Satram, S, To, TM, Mahrus, S, Sufan, RI, Albarmawi, H

February 2021

Abstract

ASCO GU Symposium

Real-world survival of men with metastatic hormone-sensitive prostate cancer treated with abiraterone acetate or docetaxel and comparison with clinical trial outcomes →

Geynisman, DM, Correa, AF, Ramamurthy, C, Beck, JR, Handorf, E

February 2021

Abstract

ASCO GU Symposium

Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer →

Marar, M, Long, Q, Mamtani, R, Narayan, V, Vapiwala, N, Parikh, RB

February 2021

Abstract

ASCO GU Symposium

The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies →

Shaw, JL, Nielson, CM, Park, JK, Marongiu, A, Soff, GA

February 2021

Manuscript

European Journal of Haematology

Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort →

Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM

May 2020

Abstract

AACR Annual Meeting

Association of BRCA alteration type with real-world outcomes to PARP inhibitors in patients with metastatic castrate-resistant prostate cancer →

Antonarakis, ES, Madison, RW, Snider, J, Snow, T, Sokol, ES, Chung, JH, McCusker, M, Singal, G, Alexander, BM, Castellanos, EH, Venstrom, JM, Schrock, AB, Ross, JS

May 2020

Abstract

ASCO Annual Meeting

Flatiron-authored